BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foy KC, Wygle RM, Miller MJ, Overholser JP, Bekaii-Saab T, Kaumaya PT. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol. 2013;191:217-227. [PMID: 23698748 DOI: 10.4049/jimmunol.1300231] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Kametani Y, Miyamoto A, Tsuda B, Tokuda Y. B Cell Epitope-Based Vaccination Therapy. Antibodies 2015;4:225-39. [DOI: 10.3390/antib4030225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Fidelle M, Yonekura S, Picard M, Cogdill A, Hollebecque A, Roberti MP, Zitvogel L. Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Front Immunol 2020;11:600886. [PMID: 33381121 DOI: 10.3389/fimmu.2020.600886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
3 Yang C, Liao W, Ho C, Chen K, Tsai T, Hsu C, Su K, Chang Y, Wu C, Hsu C, Liao B, Hsu W, Lee J, Lin C, Shih J, Yang JC, Yu C. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. European Journal of Cancer 2020;124:110-22. [DOI: 10.1016/j.ejca.2019.10.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
4 Amin M, Lockhart AC. The potential role of immunotherapy to treat colorectal cancer. Expert Opin Investig Drugs. 2015;24:329-344. [PMID: 25519074 DOI: 10.1517/13543784.2015.985376] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
5 Shih YH, Peng CL, Lee SY, Chiang PF, Yao CJ, Lin WJ, Luo TY, Shieh MJ. 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma. Oncotarget 2015;6:16601-10. [PMID: 26062654 DOI: 10.18632/oncotarget.3968] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kaumaya PTP, Guo L, Overholser J, Penichet ML, Bekaii-Saab T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology 2020;9:1818437. [PMID: 33117602 DOI: 10.1080/2162402X.2020.1818437] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Navari M, Zare M, Javanmardi M, Asadi-Ghalehni M, Modjtahedi H, Rasaee MJ. Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope. Immunopharmacol Immunotoxicol 2014;36:309-15. [PMID: 25070131 DOI: 10.3109/08923973.2014.945127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
8 Barth RF, Wu G, Meisen WH, Nakkula RJ, Yang W, Huo T, Kellough DA, Kaumaya P, Turro C, Agius LM, Kaur B. Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors. Onco Targets Ther 2016;9:2769-81. [PMID: 27274273 DOI: 10.2147/OTT.S99242] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
9 Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol 2020;16:1767-91. [PMID: 32564612 DOI: 10.2217/fon-2020-0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel) 2015;3:519-43. [PMID: 26350593 DOI: 10.3390/vaccines3030519] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
11 Guryanova SV, Khaitov RM. Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine. Front Immunol 2021;12:607178. [PMID: 33959120 DOI: 10.3389/fimmu.2021.607178] [Reference Citation Analysis]
12 Hayes DA, Kunde DA, Taylor RL, Pyecroft SB, Sohal SS, Snow ET. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS One 2017;12:e0177919. [PMID: 28591206 DOI: 10.1371/journal.pone.0177919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Wang Z, Chen X. Establishment and validation of an immune-associated signature in lung adenocarcinoma. Int Immunopharmacol 2020;88:106867. [PMID: 32799112 DOI: 10.1016/j.intimp.2020.106867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Kaufman NEM, Dhingra S, Jois SD, Vicente MDGH. Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR). Molecules 2021;26:1076. [PMID: 33670650 DOI: 10.3390/molecules26041076] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Shen M, Jiang YZ, Wei Y, Ell B, Sheng X, Esposito M, Kang J, Hang X, Zheng H, Rowicki M, Zhang L, Shih WJ, Celià-Terrassa T, Liu Y, Cristea I, Shao ZM, Kang Y. Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. Cancer Cell 2019;35:64-80.e7. [PMID: 30612941 DOI: 10.1016/j.ccell.2018.11.016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 15.3] [Reference Citation Analysis]
16 Geskovski N, Matevska-Geshkovska N, Dimchevska Sazdovska S, Glavas Dodov M, Mladenovska K, Goracinova K. The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors. Beilstein J Nanotechnol 2021;12:375-401. [PMID: 33981532 DOI: 10.3762/bjnano.12.31] [Reference Citation Analysis]
17 Shin SY, Yoon H, Hwang D, Ahn S, Kim D, Koh D, Lee YH, Lim Y. Benzochalcones bearing pyrazoline moieties show anti-colorectal cancer activities and selective inhibitory effects on aurora kinases. Bioorganic & Medicinal Chemistry 2013;21:7018-24. [DOI: 10.1016/j.bmc.2013.09.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
18 Pandey JP, Kistner-Griffin E, Radwan FF, Kaur N, Namboodiri AM, Black L, Butler MA, Carreon T, Ruder AM. Endogenous antibody responsiveness to epidermal growth factor receptor is associated with immunoglobulin allotypes and overall survival of patients with glioblastoma. Neuro Oncol 2015;17:678-84. [PMID: 25326496 DOI: 10.1093/neuonc/nou298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Wang A, Cui M, Qu H, Di J, Wang Z, Xing J, Wu F, Wu W, Wang X, Shen L, Jiang B, Su X. Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab. Oncotarget 2016;7:75293-306. [PMID: 27659529 DOI: 10.18632/oncotarget.12167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
20 Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology 2014;3:e956012. [PMID: 25941588 DOI: 10.4161/21624011.2014.956012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
21 Kaumaya PT. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother 2015;11:1368-86. [PMID: 25874884 DOI: 10.1080/21645515.2015.1026495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
22 Gautam N, Elleson KM, Ramamoorthi G, Czerniecki BJ. Current State of Cell Therapies for Breast Cancer. Cancer J 2022;28:301-9. [PMID: 35880940 DOI: 10.1097/PPO.0000000000000607] [Reference Citation Analysis]
23 Sachdeva S, Joo H, Tsai J, Jasti B, Li X. A Rational Approach for Creating Peptides Mimicking Antibody Binding. Sci Rep 2019;9:997. [PMID: 30700733 DOI: 10.1038/s41598-018-37201-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
24 Uddin MZ, Li X, Joo H, Tsai J, Wrischnik L, Jasti B. Rational Design of Peptide Ligands Based on Knob–Socket Protein Packing Model Using CD13 as a Prototype Receptor. ACS Omega 2019;4:5126-36. [DOI: 10.1021/acsomega.8b03421] [Reference Citation Analysis]
25 Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. World J Gastroenterol 2018; 24(48): 5418-5432 [PMID: 30622371 DOI: 10.3748/wjg.v24.i48.5418] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
26 Kaumaya PT. Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics. Immunotherapy 2013;5:1159-63. [PMID: 24188668 DOI: 10.2217/imt.13.128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
27 Kanthala S, Banappagari S, Gokhale A, Liu YY, Xin G, Zhao Y, Jois S. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer. Chem Biol Drug Des 2015;85:702-14. [PMID: 25346057 DOI: 10.1111/cbdd.12453] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
28 Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, Kaumaya PT. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides. Oncoimmunology 2014;3:e956005. [PMID: 25941587 DOI: 10.4161/21624011.2014.956005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
29 Jin D, Yu X, Chen B, Li Z, Ding J, Zhao X, Qi G. Combined immunotherapy of breast cancer with EGF and VEGF vaccines from DNA shuffling in a mouse model. Immunotherapy 2017;9:537-53. [PMID: 28509606 DOI: 10.2217/imt-2017-0004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
30 Wang SS, Liu W, Ly D, Xu H, Qu L, Zhang L. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol 2019;16:6-18. [PMID: 29628498 DOI: 10.1038/s41423-018-0027-x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 78] [Article Influence: 17.3] [Reference Citation Analysis]